We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current XERS market cap is 247.2M. The company's latest EPS is USD -0.4432 and P/E is -4.02.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |||
| Total Revenue | 29.73M | 33.14M | 33.2M | 38.01M | 48.32M |
| Operating Income | -18.78M | -15.17M | -13.28M | -15.98M | -4.91M |
| Net Income | -21.83M | -12.93M | -16.83M | -19.84M | -12.19M |
| Year End 31 December 2023 | 2021 | 2022 | 2023 |
|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 49.59M | 110.25M | 163.91M |
| Operating Income | -115.16M | -81.94M | -44.01M |
| Net Income | -122.73M | -94.66M | -62.26M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |||
| Total Assets | 303.02M | 344.52M | 321.36M | 328.78M | 327.78M |
| Total Liabilities | 247.98M | 299.34M | 291.31M | 315.14M | 323.92M |
| Total Equity | 55.04M | 45.19M | 30.05M | 13.64M | 3.87M |
| Year End 31 December 2023 | 2021 | 2022 | 2023 |
|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 304.36M | 344.52M | 322.6M |
| Total Liabilities | 209.13M | 299.34M | 329.38M |
| Total Equity | 95.23M | 45.19M | -6.78M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |||
| Operating | -86.77M | -102.89M | -26.14M | -39.88M | -54.49M |
| Investing | 25.29M | 34.46M | -43.98M | -35.53M | -20.87M |
| Financing | 78.32M | 127.47M | -863k | -307k | -379k |
| Year End 31 December 2023 | 2021 | 2022 | 2023 |
|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |
| Operating | -95.54M | -102.89M | -47.02M |
| Investing | 97.96M | 34.46M | -6M |
| Financing | 27.25M | 127.47M | -1.61M |
| Market Cap | 247.2M |
| Price to Earnings Ratio | -4.02 |
| Price to Sales Ratio | 1.53 |
| Price to Cash Ratio | 3.71 |
| Price to Book Ratio | -36.86 |
| Dividend Yield | - |
| Shares Outstanding | 140.45M |
| Average Volume (1 week) | 1.73M |
| Average Volume (1 Month) | 1.46M |
| 52 Week Change | -26.97% |
| 52 Week High | 3.26 |
| 52 Week Low | 1.46 |
| Spread (Intraday) | 0.08 (4.35%) |
| Company Name | Xeris Biopharma Holdings Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.xerispharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
